Biontech Se Sponsored Adr Stock News

Germany’s BioNTech should be able to adapt its coronavirus vaccine relatively quickly in response to the emergence of the Omicron variant. The new coronavirus variant might be able to infect vaccinated people and will most likely be able to infect people with high exposure. It is not clear whether this variant produces more severe disease. … The post COVID: BioNTech says possible to adapt vaccine for Omicron quickly appeared first on Gulf Insider .

BioNTech should be able to adapt its coronavirus vaccine relatively quickly in response to the Omicron variant, and the next few weeks will show how urgently an upgrade is needed, its CEO Ugur Sahin told the Reuters Next conference on Friday. Sahin said people should continue to seek the established shot, developed with Pfizer, as [] The post BioNTech CEO Says Vaccine Upgrade On The Cards, Ready To Move Quickly appeared first on InsideBusiness - Business News in Nigeria .

German biotech company BioNTech should be able to adapt its coronavirus vaccine relatively quickly in response to the Omicron variant , said its CEO Ugur Shahin, adding that despite the mutations, the vaccines must continue to protect people against serious illness. BioNTech and Pfizer Inc. together created one of the first vaccines against Covid-19, with more than 2 billion doses already available to humans worldwide. However, there are concerns that vaccines may not work as well against the Omicron variant, which appeared last month. "This option may be able to infect vaccinated people. However, we expect that infected people who have been vaccinated can still be protected against serious illness," Shahin said in an interview with Friday''s Reuters Next conference. The chief executive of BioNTech, whose work until the advent of the Covid-19 coronavirus in 2020 focused on cancer, said the new variant came earlier than expected. "This highly mutant coronavirus came earlier than I expected.

FDA Expedites Review Process For Omicron Vaccines And Drugs It''s been one week since the omicron variant first rattled markets and prompted the Federal Reserve''s latest rethink of its plans for rolling back its monetary stimulus. And in that time, vaccine-makers have talked their book by sharing plans to produce new omicron-targeted vaccines, while others claim that there are no data suggesting the Pfizer-BioNTech jab is less effective against omicron. Assuming the world still does care about omicron three months from now (the first cases of the variant have only just been confirmed in the US in recent days), the FDA and its advisors are reportedly working on an expedited approval process that will allow "tweaked" versions of extant vaccines and remedies to be sheperded through in a matter of weeks. WSJ reports that the FDA has been quietly meeting with drug makers to establish guidelines for expedited approval of the next generation of vaccines, if they''re needed (and that''s still a big "if").

The German company BioNTech, which has developed a coronavirus vaccine together with its US partner Pfizer, is ready to adapt its vaccine to the omicron strain, director-general and co-founder of the pharmaceutical company Ugur Shahin said on December 3

Private Advisor Group LLC increased its stake in shares of BioNTech SE (NASDAQ:BNTX) by 9.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,231 shares of the companys stock after purchasing an additional 1,263 shares during the quarter. Private []

The Women of Europe Awards have been given and the co-founder of the German biotechnology company BioNTech, Özlem Türeci, has been awarded as a woman in business, Belgian news portal EurActiv reports. The award ceremony organised by the European Movement International and the European Womens Lobby was held on Wednesday, December 1. Türeci and her [] The post Women of Europe Award received by BioNTech co-founder appeared first on Baltic News Network - News from Latvia, Lithuania, Estonia .

The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples.

BioNTech CEO: I think we will need a new vaccine against COVID-19 ForexLive www.forexlive.com The post BioNTech CEO: I think we will need a new vaccine against COVID-19 ForexLive appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .

https://www.investing.com/news/stock-market-news/biontech-ceo-says-can-adapt-vaccine-quickly-for-omicron-2698715

while speaking at an event organized by Reuters on Friday, BioNTech CEO Ugur Sahin said the new variant might be able to infect vaccinated people and

BioNTech CEO, Ugur Sahin, remarks

The Omicron variant ignites fears that currently available COVID-19 vaccines and treatments could be less effective against it. MRNA, PFE, BNTX, REGN and JNJ are some of the industry players gearing u

The Wall Street Journal is reporting that the FDA is laying the ground work for a quick review of omicron-targeted vaccines and drugs, if needed.